Literature DB >> 31268627

Exploratory Study of MYD88 L265P, Rare NLRP3 Variants, and Clonal Hematopoiesis Prevalence in Patients With Schnitzler Syndrome.

Shelly Pathak1, Dorota M Rowczenio2, Roger G Owen3, Gina M Doody4, Darren J Newton4, Claire Taylor4, Jan Taylor3, Catherine Cargo3, Philip N Hawkins2, Karoline Krause5, Helen J Lachmann2, Sinisa Savic1.   

Abstract

OBJECTIVE: To assess the prevalence of the MYD88 L265P mutation and variants within NLRP3 and evaluate the status of oligoclonal hematopoiesis in 30 patients with Schnitzler syndrome (SchS).
METHODS: Thirty patients with SchS were recruited from 3 clinical centers. Six patients with known acquired cryopyrin-associated periodic syndromes (aCAPS) were included as controls. Allele-specific oligonucleotide-polymerase chain reaction was used for the detection of the MYD88 L265P variant, next-generation sequencing was applied to analyze NLRP3 and 28 genes associated with myelodysplastic syndrome, and gene scanning was performed for the detection of X chromosome inactivation.
RESULTS: Activating NLRP3 mutations were not present in 11 SchS patients who had not been sequenced for this gene previously. The MYD88 L265P variant was present in 9 of 30 SchS patients, and somatic mutations associated with clonal hematopoiesis were identified in 1 of 30 patients with SchS and 1 of 6 patients with aCAPS. Evidence of nonrandom X chromosome inactivation was detected in 1 female patient with SchS and 1 female patient with aCAPS.
CONCLUSION: A shared molecular mechanism accounting for the pathogenesis of inflammation in SchS remains elusive. Clonal hematopoiesis is not associated with other somatic mutations found in individuals with SchS or aCAPS.
© 2019, American College of Rheumatology.

Entities:  

Year:  2019        PMID: 31268627     DOI: 10.1002/art.41030

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  9 in total

Review 1.  Somatic mutations in rheumatological diseases: VEXAS syndrome and beyond.

Authors:  Keith A Sikora; Kristina V Wells; Ertugrul Cagri Bolek; Adrianna I Jones; Peter C Grayson
Journal:  Rheumatology (Oxford)       Date:  2022-08-03       Impact factor: 7.046

Review 2.  Hereditary systemic autoinflammatory diseases and Schnitzler's syndrome.

Authors:  Mark Kacar; Shelly Pathak; Sinisa Savic
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

3.  Evidence of B Cell Clonality and Investigation Into Properties of the IgM in Patients With Schnitzler Syndrome.

Authors:  Shelly Pathak; Dorota Rowczenio; Samuel Lara-Reyna; Mark Kacar; Roger Owen; Gina Doody; Karoline Krause; Helen Lachmann; Rainer Doffinger; Darren Newton; Sinisa Savic
Journal:  Front Immunol       Date:  2020-12-03       Impact factor: 7.561

Review 4.  Aging, Bone Marrow and Next-Generation Sequencing (NGS): Recent Advances and Future Perspectives.

Authors:  Payal Ganguly; Bradley Toghill; Shelly Pathak
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

Review 5.  Cutaneous manifestations of monoclonal gammopathy.

Authors:  Jean-Sebastien Claveau; David A Wetter; Shaji Kumar
Journal:  Blood Cancer J       Date:  2022-04-11       Impact factor: 11.037

6.  Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.

Authors:  Yuehua Huang; Yanying Wang; Fan Yu; Xuehan Mao; Bianhong Wang; Jingxian Li; Lihong Li
Journal:  Front Immunol       Date:  2022-04-20       Impact factor: 8.786

Review 7.  IgM monoclonal gammopathies of clinical significance: diagnosis and management.

Authors:  Jahanzaib Khwaja; Shirley D'Sa; Monique C Minnema; Marie José Kersten; Ashutosh Wechalekar; Josephine M Vos
Journal:  Haematologica       Date:  2022-09-01       Impact factor: 11.047

Review 8.  Improving Diagnosis and Clinical Management of Acquired Systemic Autoinflammatory Diseases.

Authors:  Adam Al-Hakim; Anoop Mistry; Sinisa Savic
Journal:  J Inflamm Res       Date:  2022-10-10

Review 9.  Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.

Authors:  Zoltán Szekanecz; Iain B McInnes; Georg Schett; Szilvia Szamosi; Szilvia Benkő; Gabriella Szűcs
Journal:  Nat Rev Rheumatol       Date:  2021-08-02       Impact factor: 20.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.